In the multivariate analysis, only Hb level and thyroid cancer incidence increased the risk of second primary cancer in the NAFLD patient group, DL patient group, and overall patient group (Table 3). The gene discussed is GSTM1; the disease is metabolic dysfunction-associated steatotic liver disease.